Automated Breast Ultrasound Market Size, Share, Growth, and Industry Analysis, By Type (Automated Breast Ultrasound System,Automated Breast Volume Scanner), By Application (Hospitals,Diagnostic Imaging Laboratories), Regional Insights and Forecast to 2035

Automated Breast Ultrasound Market Overview

The global Automated Breast Ultrasound Market is forecast to expand from USD 1587.13 million in 2026 to USD 1814.57 million in 2027, and is expected to reach USD 5297.29 million by 2035, growing at a CAGR of 14.33% over the forecast period.

The global Automated Breast Ultrasound (ABUS) market is witnessing robust growth, driven by the rising incidence of breast cancer, increasing awareness of early diagnosis, and continuous advancements in diagnostic imaging technologies. With more than 2.3 million new breast cancer cases reported globally, healthcare providers are increasingly adopting ABUS systems for their superior ability to detect small tumors in women with dense breast tissue. Compared to conventional handheld ultrasound, ABUS improves lesion detection while offering standardized image acquisition, reduced operator dependency, and enhanced workflow efficiency. The integration of artificial intelligence, 3D image reconstruction, and automated scanning technologies has further improved diagnostic accuracy and reduced examination times, supporting wider adoption across hospitals and diagnostic imaging centers.

North America remains the leading regional market, driven by strong healthcare infrastructure, widespread breast cancer screening programs, and rapid adoption of AI-enabled imaging technologies, while Europe and Asia-Pacific continue to expand through increasing investments in women's healthcare and government-supported screening initiatives. In the United States, the market benefits from high annual screening participation, growing implementation of breast density notification laws, and FDA-approved ABUS systems from major manufacturers. Rising installations across hospitals and imaging centers, combined with ongoing innovation in image quality, compact system design, and AI-assisted diagnostics, are positioning Automated Breast Ultrasound as a key technology for improving early breast cancer detection and advancing precision diagnostic imaging worldwide.

What is Automated Breast Ultrasound?

Automated Breast Ultrasound (ABUS) is an advanced medical imaging technology used to screen and detect breast cancer, especially in women with dense breast tissue where traditional mammography may be less effective. Unlike handheld ultrasound, ABUS uses a fully automated scanning system that captures high-resolution, 3D images of the entire breast. These images are then reconstructed and analyzed by radiologists, often with the help of AI-based software, to identify abnormalities such as tumors or lesions.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Rising breast cancer screening programs and AI-enabled imaging adoption are driving market growth, with screening participation increasing by 45% globally.
• Major Market Restraint: High equipment costs and limited reimbursement continue to hinder adoption, affecting approximately 28% of potential market expansion.
• Emerging Trends: AI-powered lesion detection is the leading trend, with adoption reaching 54% across advanced ABUS systems.
• Regional Leadership: North America leads the global Automated Breast Ultrasound market with 42% market share.
• Competitive Landscape: The top five manufacturers collectively account for 63% of the global market share.
• Market Segmentation: Hospitals dominate the market, representing 65% of total ABUS system installations.
• Recent Development: AI-powered ABUS product launches increased by 33% between 2023 and 2025, accelerating market innovation.

Automated Breast Ultrasound Market Latest Trends

The Automated Breast Ultrasound (ABUS) market is undergoing rapid technological transformation, primarily driven by the integration of AI-powered diagnostics, advanced imaging algorithms, and automation. Between 2023 and 2025, AI adoption in ABUS systems has increased by 40%, significantly improving lesion detection accuracy and diagnostic confidence. Modern systems now enable full breast scanning in under 60 seconds, reducing examination time by 35% and improving clinical workflow efficiency. In addition, advanced 3D reconstruction technologies have enhanced image clarity and processing speed by 50%, allowing radiologists to evaluate more patients daily while maintaining high diagnostic precision.

Another key trend shaping the market is the growing shift toward hybrid imaging, portable devices, and cloud-based diagnostic platforms. Hybrid use of ABUS with digital mammography has increased by 28% year-over-year, strengthening its role in secondary screening, particularly for women with dense breast tissue, where usage has risen by 32%. Cloud-based image storage solutions have also expanded by 41%, improving accessibility and data sharing among healthcare providers. Meanwhile, the introduction of over 15 new portable ABUS models between 2023 and 2025 reflects rising demand for flexible, high-efficiency imaging solutions aimed at reducing false positives and improving overall screening outcomes.

Automated Breast Ultrasound Market Dynamics

DRIVER

"Rising demand for early breast cancer detection."

Rising demand for early breast cancer detection is a major driver of the Automated Breast Ultrasound (ABUS) market. Growing awareness about breast cancer has significantly increased global screening rates, with more than 70% of women aged 40 and above in developed countries undergoing routine imaging. As breast cancer remains the most diagnosed cancer among women, with around 2.3 million new cases annually, healthcare systems are prioritizing early and accurate detection to improve survival outcomes. ABUS technology supports this need by offering a 37% higher detection rate of small lesions compared to handheld ultrasound, particularly in dense breast tissue where traditional imaging is less effective.

In addition, technological advancements are further strengthening market growth. The integration of artificial intelligence has improved reading efficiency by approximately 30%, enabling faster and more accurate interpretation of imaging results. Automated workflows also reduce examination time, increasing patient throughput in hospitals and diagnostic centers. These improvements in accuracy, speed, and efficiency are making ABUS an essential tool in modern breast cancer screening programs globally.

RESTRAINT

"High installation and maintenance costs."

A key restraint in the ABUS market is the high cost of installation and ongoing maintenance. ABUS systems are approximately 45% more expensive than conventional ultrasound machines, which creates a significant financial burden for healthcare providers, especially in low- and middle-income countries. This high capital investment limits adoption among smaller hospitals and diagnostic centers, restricting overall market penetration despite the technology’s clinical advantages.

Another major challenge is the shortage of skilled professionals required to operate ABUS systems effectively. In many regions, particularly rural areas, only about 55% of imaging centers have adequately trained personnel. This skills gap, combined with budget constraints, slows down adoption and limits the efficient use of advanced imaging systems. As a result, many healthcare facilities continue to rely on traditional ultrasound methods instead of transitioning to automated solutions.

OPPORTUNITY

"Expansion in AI-based imaging diagnostics."

The expansion of AI-based imaging diagnostics presents a strong opportunity for the ABUS market. More than 50% of manufacturers are actively investing in artificial intelligence integration, with clinical studies showing diagnostic accuracy reaching up to 95%. AI enhances lesion detection, supports automated image interpretation, and improves workflow efficiency, making ABUS systems more reliable and clinically effective.

Additionally, the growing adoption of digital healthcare solutions such as telemedicine and cloud-based imaging platforms is expanding access to advanced diagnostic services. These technologies allow remote image sharing, consultation, and analysis, particularly benefiting underserved and rural regions. As healthcare systems continue to modernize, AI-enabled ABUS solutions are expected to play a key role in improving accessibility, efficiency, and diagnostic precision.

CHALLENGE

"Integration with existing imaging infrastructure."

One of the main challenges in the ABUS market is integrating the technology with existing imaging infrastructure. Around 30% of healthcare facilities report interoperability issues when combining ABUS systems with digital mammography and other diagnostic platforms. These compatibility issues can disrupt workflow efficiency and limit the full potential of automated imaging solutions in clinical settings.

In addition, integration with hospital data systems such as PACS (Picture Archiving and Communication Systems) requires technical adjustments and specialized training for radiologists. Limited awareness in developing regions and inconsistent reimbursement policies further complicate adoption. These factors collectively slow down large-scale implementation of ABUS technology despite its strong clinical benefits.

Why is Demand Increasing for the Automated Breast Ultrasound Industry?

Demand for the Automated Breast Ultrasound (ABUS) industry is increasing primarily due to the rising global burden of breast cancer and the need for more accurate early detection methods. With more than 2.3 million new breast cancer cases annually, healthcare systems are prioritizing advanced imaging technologies that can detect tumors at an early stage, especially in women with dense breast tissue where traditional mammography is less effective. ABUS improves lesion detection accuracy by about 37% compared to handheld ultrasound and offers standardized 3D imaging with reduced operator dependency, making it highly reliable for large-scale screening programs. In addition, growing awareness among women aged 40 and above has led to screening participation rates exceeding 70% in developed countries, further boosting adoption.

Automated Breast Ultrasound Market Segmentation

The Automated Breast Ultrasound Market is segmented by type into Automated Breast Ultrasound Systems (ABUS) and Automated Breast Volume Scanners (ABVS), and by application into Hospitals and Diagnostic Imaging Laboratories, reflecting diverse clinical utilization and adoption patterns globally.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Automated Breast Ultrasound System (ABUS): Automated Breast Ultrasound Systems account for 42% of the global market and are widely used for full-breast 3D imaging in hospitals and diagnostic centers. These systems significantly improve detection accuracy by around 37% in dense breast tissue and reduce examination time by nearly 30%, making them highly efficient for clinical workflows. Increasing integration of artificial intelligence has further enhanced performance, with more than 45% of ABUS devices now featuring automated image interpretation. This has improved diagnostic consistency and reduced operator dependency across healthcare facilities.

The segment is projected to reach a market size of USD 656.7 million by 2034, growing steadily due to rising demand for early breast cancer detection and advanced imaging solutions. The United States leads this segment, followed by Germany, Japan, the United Kingdom, and France, driven by strong screening programs and hospital adoption. Continuous advancements in AI-based imaging, combined with growing awareness of breast cancer, are expected to further strengthen adoption. Expansion of digital healthcare infrastructure is also supporting long-term segment growth.

Automated Breast Volume Scanner (ABVS): Automated Breast Volume Scanners dominate the market with a 58% share, offering superior volumetric imaging capabilities for comprehensive breast cancer screening. These systems capture between 300–500 image slices per scan, improving lesion visibility by about 40% compared to conventional ultrasound. ABVS is widely preferred in diagnostic imaging laboratories due to its high accuracy and suitability for secondary screening applications. Usage has increased significantly, supported by advancements in 3D imaging and automation technologies.

The ABVS segment is expected to reach USD 877.3 million by 2034, driven by rapid adoption in high-volume diagnostic centers and growing investment in AI-enabled imaging systems. The United States, China, Germany, Japan, and India are the leading countries in this segment due to strong healthcare infrastructure and expanding screening programs. Increasing demand for precise volumetric analysis and early detection of breast abnormalities is further accelerating growth. Continuous innovation in imaging resolution and workflow efficiency is expected to sustain long-term expansion.

BY APPLICATION

Hospitals: Hospitals represent 65% of global ABUS system adoption, making them the leading application segment due to their large-scale diagnostic capabilities and advanced imaging infrastructure. More than 1,800 hospitals worldwide utilize ABUS technology for breast cancer screening, significantly reducing diagnosis time by around 33%. The integration of AI-based imaging systems has improved workflow efficiency and enhanced detection accuracy, particularly for dense breast tissue cases. Hospital-based screening programs continue to expand as demand for early cancer detection increases globally.

The hospital segment is projected to reach USD 3,010.5 million by 2034, supported by strong adoption of automated imaging systems and government-led screening initiatives. The United States leads this segment, followed by Germany, Japan, China, and the United Kingdom, driven by advanced healthcare systems and high patient volumes. Increasing investment in digital imaging infrastructure and AI-assisted diagnostics is further strengthening hospital adoption. Continued expansion of public health screening programs is expected to sustain long-term growth.

Diagnostic Imaging Laboratories: Diagnostic imaging laboratories account for 35% of the global ABUS market and are increasingly adopting automated systems for high-precision breast cancer screening. The number of imaging labs using ABUS and ABVS technologies has increased by 29% in recent years, driven by the need for standardized, high-throughput diagnostic solutions. These laboratories benefit from improved early detection rates of around 36%, along with enhanced workflow efficiency and consistent imaging quality across patients. Growing reliance on AI-based imaging is further improving diagnostic accuracy.

This segment is projected to reach USD 1,623.0 million by 2034, supported by rising demand for advanced screening technologies in private diagnostic centers. The United States leads the segment, followed by China, Germany, Japan, and India, driven by expanding imaging networks and healthcare digitization. Increasing investments in AI-powered radiology and volumetric scanning systems are accelerating adoption. Continuous growth in outpatient diagnostic services is expected to further strengthen this segment globally.

Which Segment is Growing Faster?

The fastest-growing segment in the Automated Breast Ultrasound (ABUS) market is the Automated Breast Volume Scanner (ABVS) within the type category. ABVS is expanding at a higher CAGR of 14.70%, driven by its superior volumetric imaging capability, higher lesion visibility, and strong adoption in high-volume diagnostic imaging laboratories. Its ability to capture detailed 3D breast slices (300–500 per scan) and improve detection accuracy by around 40% is making it increasingly preferred for advanced breast cancer screening, especially in technologically mature healthcare systems.

Automated Breast Ultrasound Market Regional Outlook

The Automated Breast Ultrasound Market shows strong regional performance, led by North America and Europe, with rapid expansion across Asia-Pacific and rising adoption in the Middle East & Africa through advanced screening initiatives.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

NORTH AMERICA

North America holds the dominant position in the Automated Breast Ultrasound market with a 42% share, supported by advanced healthcare infrastructure and high breast cancer screening participation rates exceeding 70% among women aged 40–65. The region benefits from strong adoption of AI-enabled ABUS systems, with more than 1,500 installations in the United States alone. Increasing integration of artificial intelligence has improved diagnostic accuracy, workflow efficiency, and early cancer detection across hospitals and imaging centers. Rising awareness of breast density-related risks is further accelerating screening demand.

The market is expected to reach USD 1,945.2 million by 2034, driven by continuous technological advancements and government-backed early detection programs. The United States leads the region, followed by Canada, Mexico, Brazil, and Chile, supported by expanding healthcare access and private sector investments. High adoption of digital imaging systems and precision diagnostics continues to strengthen regional growth. The presence of leading medical technology companies further reinforces North America’s leadership in the global market.

EUROPE

Europe accounts for 29% of the global Automated Breast Ultrasound market, driven by strong healthcare systems and increasing breast cancer awareness across countries like Germany, the UK, France, Italy, and Spain. Breast density notification policies in multiple European nations have increased screening rates and awareness by 26% since 2022. The region has also seen a 31% rise in AI-integrated ABUS adoption, improving diagnostic precision and reducing false-positive rates. Expanding government-supported screening programs continue to enhance early detection efforts.

The market is projected to reach USD 1,344.8 million by 2034, supported by modernization of hospital imaging infrastructure and strong regulatory frameworks. Germany leads the region, followed by the United Kingdom, France, Italy, and Spain, all contributing significantly to market expansion. Continuous investments in digital healthcare and AI-based diagnostic systems are improving efficiency and patient outcomes. Growing cross-border healthcare collaboration further supports regional market development.

ASIA-PACIFIC

Asia-Pacific holds 22% of the global Automated Breast Ultrasound market and is one of the fastest-growing regions due to rising breast cancer incidence and rapid healthcare modernization. With over 800,000 new breast cancer cases annually, demand for advanced screening technologies is increasing significantly. Countries like China, Japan, India, South Korea, and Australia are leading adoption, supported by expanding hospital networks and government screening initiatives. ABUS installation rates have increased by 31% since 2023.

The market is expected to reach USD 1,019.4 million by 2034, driven by strong investments in digital health infrastructure and AI-based imaging technologies. China leads the region, followed by Japan and India, which together account for a major share of regional demand. Rising healthcare awareness, urbanization, and expanding private diagnostic centers are accelerating growth. Continuous technological innovation is further improving accessibility and diagnostic accuracy across the region.

MIDDLE EAST & AFRICA

The Middle East & Africa region accounts for 7% of the Automated Breast Ultrasound market, with growing adoption in countries such as the UAE, Saudi Arabia, South Africa, Egypt, and Israel. Increasing government awareness programs have improved early detection initiatives by 19%, while healthcare infrastructure investments have grown by 25%. The region is witnessing gradual adoption of AI-enabled ABUS systems, particularly in urban hospitals and private diagnostic centers. Demand is rising among women aged 35–55 due to increasing awareness of breast cancer screening.

The market is projected to reach USD 324.1 million by 2034, supported by expanding healthcare modernization and rising investment in diagnostic technologies. The UAE leads the region, followed by Saudi Arabia, South Africa, Egypt, and Israel, each contributing to steady market growth. Increased adoption of advanced imaging systems in private healthcare facilities is strengthening regional expansion. Ongoing improvements in healthcare access and digital transformation are expected to further drive growth.

Which region holds the largest market share?

The region that holds the largest market share in the Automated Breast Ultrasound (ABUS) market is North America, accounting for 42% of the global market share. This dominance is driven mainly by the United States, which has high breast cancer screening rates (over 70% among women aged 40–65), widespread adoption of AI-enabled ABUS systems, and more than 1,500 installed systems across hospitals and imaging centers. Strong healthcare infrastructure, early adoption of advanced imaging technologies, and government-supported screening programs further reinforce North America’s leading position in the global market.

List of Top Automated Breast Ultrasound Companies

• Koninklijke Philips N.V.
• Telemed Medical Systems
• Hitachi Ltd.
• Siemens Healthineers AG
• Fukuda Denshi
• General Electric Company
• Canon Medical Systems Corporation
• Hologic Inc.

Top Two companies with the highest market share:

• Koninklijke Philips N.V. – Holds approximately 18% of the global market share with advanced imaging integration and AI-based diagnostics.
• GE Healthcare (General Electric Company) – Accounts for around 21% share, leading in the U.S. and Europe with over 500 ABUS installations across hospitals.

Investment Analysis and Opportunities

The Automated Breast Ultrasound Market Forecast indicates rising investment in next-generation imaging systems focusing on automation, AI, and digital data management. Over 45% of leading imaging equipment manufacturers have increased R&D expenditure between 2023 and 2025. Healthcare providers are allocating more than 25% of diagnostic imaging budgets toward automated breast imaging technology.

Emerging markets such as India, Brazil, and the UAE are investing heavily in healthcare infrastructure, leading to a 35% increase in ABUS procurement tenders. Government funding initiatives and collaborations between public hospitals and private manufacturers have improved accessibility to ABUS systems. The integration of ABUS with PACS and cloud-based diagnostic tools also presents major investment opportunities, enabling real-time diagnosis and teleconsultation.

Additionally, venture capital investments in AI-driven medical imaging startups have increased by 40% since 2023, driving innovation in automated detection algorithms. Hospitals and imaging centers are focusing on upgrading equipment with hybrid imaging capabilities, creating new revenue opportunities across the value chain of breast imaging diagnostics.

New Product Development

The ABUS market has witnessed substantial innovation between 2023 and 2025, focusing on device compactness, portability, and artificial intelligence. Manufacturers have launched over 12 new models featuring AI-enabled lesion detection and 3D volumetric scanning capabilities. For instance, newer systems can capture up to 500 image slices per scan, offering superior tissue differentiation accuracy.

Leading companies have introduced handheld-compatible ABUS systems weighing less than 20 kilograms, improving mobility and accessibility in smaller clinics. Moreover, new cloud-integrated platforms enable seamless data sharing among radiologists, with 40% adoption in advanced healthcare facilities. The integration of deep learning algorithms has enhanced diagnostic sensitivity by 18%, minimizing false positives.

Recent innovations include real-time elastography and automated compression control, reducing patient discomfort by 25% during scanning. These developments are enhancing workflow efficiency, making ABUS a preferred choice for mass screening programs and hospital-based imaging centers worldwide.

Five Recent Developments

• GE Healthcare launched a next-generation AI-powered ABUS system in 2024, improving lesion detection accuracy by 21%.
• Siemens Healthineers introduced an upgraded 3D ABVS platform in 2023, enhancing image processing speed by 40%.
• Philips integrated deep-learning algorithms into its ABUS units in 2025, increasing workflow efficiency by 35%.
• Hologic, Inc. released a compact ABUS scanner for outpatient settings in 2024, cutting scan times by 28%.
• Canon Medical Systems launched hybrid ABUS-MRI integration software in 2025, improving cross-modality diagnostics by 30%.

Report Coverage of Automated Breast Ultrasound Market

The Automated Breast Ultrasound Market Research Report provides a comprehensive analysis of the industry structure, segmentation, regional dynamics, and key competitive developments. The report covers detailed market insights, highlighting current trends, technological advancements, and adoption rates across hospitals and diagnostic laboratories.

It offers in-depth data on product innovations, regional demand patterns, and emerging opportunities across North America, Europe, Asia-Pacific, and the Middle East & Africa. With over 25 manufacturers analyzed, the report evaluates market share, technological competitiveness, and growth potential across multiple segments.

The Automated Breast Ultrasound Market Outlook focuses on clinical adoption rates, integration of artificial intelligence, and regulatory landscape across major economies. Additionally, it provides investment insights, identifying growth opportunities in AI-based imaging, portable ABUS devices, and hybrid breast imaging systems. Covering data from 2020–2025, the report delivers essential market intelligence for investors, manufacturers, and healthcare providers seeking to understand the evolving landscape of automated breast ultrasound technology.

Automated Breast Ultrasound Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1587.13 Million in 2026
Market Size Value By	USD 5297.29 Million by 2035
Growth Rate	CAGR of 14.33% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Automated Breast Ultrasound System Automated Breast Volume Scanner By Application : Hospitals Diagnostic Imaging Laboratories
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample